当前位置: X-MOL 学术J. Med. Chem. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Development of PSMA-1007-Related Series of 18F-Labeled Glu-Ureido-Type PSMA Inhibitors.
Journal of Medicinal Chemistry ( IF 6.8 ) Pub Date : 2020-08-27 , DOI: 10.1021/acs.jmedchem.9b01479
Jens Cardinale 1 , Mareike Roscher 1 , Martin Schäfer 1 , Max Geerlings 1 , Martina Benešová 1 , Ulrike Bauder-Wüst 1 , Yvonne Remde 1 , Matthias Eder 1 , Zora Nováková 2 , Lucia Motlová 2 , Cyril Barinka 2 , Frederik L Giesel 3 , Klaus Kopka 4
Affiliation  

In recent years, a number of drugs targeting the prostate-specific membrane antigen (PSMA) have become important tools in the diagnosis and treatment of prostate cancer. In the present work, we report on the synthesis and preclinical evaluation of a series of 18F-labeled PSMA ligands for diagnostic application based on the theragnostic ligand PSMA-617. By applying modifications to the linker structure, insight into the structure–activity relationship could be gained, highlighting the importance of hydrophilicity and stereoselectivity on interaction with PSMA and hence the biodistribution. Selected compounds were co-crystallized with the PSMA protein and analyzed by X-rays with mixed results. Among these, PSMA-1007 (compound 5) showed the best interaction with the PSMA protein. The respective radiotracer [18F]PSMA-1007 was translated into the clinic and is, in the meantime, subject of advanced clinical trials.

中文翻译:

与PSMA-1007相关的18F标签Glu-Ureido型PSMA抑制剂系列的开发。

近年来,许多靶向前列腺特异性膜抗原(PSMA)的药物已成为诊断和治疗前列腺癌的重要工具。在本工作中,我们报告了基于Theragnostic配体PSMA-617的一系列18 F标记的PSMA配体的合成和临床前评估,以用于诊断应用。通过对接头结构进行修饰,可以深入了解结构与活性之间的关系,从而突出了亲水性和立体选择性对与PSMA相互作用以及由此产生的生物分布的重要性。所选化合物与PSMA蛋白共结晶,并通过X射线分析得到混合结果。其中,PSMA-1007(化合物5)与PSMA蛋白相互作用最好。各自的放射性示踪剂[18 F] PSMA-1007已翻译成临床,同时正在接受高级临床试验。
更新日期:2020-10-08
down
wechat
bug